CoChat

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy

Antohe, Jana l., Bili, Androniki, Sartorius, Jennifer A., Kirchner, H. Lester, Morris, Stephanie J., Dancea, Sorina, Wasko, Mary Chester M. · 2012 · Arthritis Care & Research
Cited by 90

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: To examine the association of tumor necrosis factor α (TNFα) inhibitor use and the risk of developing diabetes mellitus in a rheumatoid arthritis (RA) inception cohort. Methods: Adults diagnosed with RA between January 1, 2001, and December 31, 2009, were identified (n = 1,881). Prevalent cases of diabetes mellitus (n = 294) were excluded. Information on sociodemographic data, medical history, body mass index (BMI), laboratory measures, and medications was collected from the electronic health record. Incident diabetes mellitus was defined using the 2010 American Diabetes Association criteria or physician‐established diagnosis. Time‐varying Cox proportional hazards regression models were used to adjust for age, sex, race, BMI, rheumatoid factor (RF) and anti–cyclic citrullinated peptide antibodies (anti‐CCP), erythrocyte sedimentation rate (ESR), and use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, and methotrexate. Results: A total of 1,587 incident RA patients without diabetes mellitus were included. The anti‐TNFα users (n = 522) had a lower median age but greater baseline BMI; maximum ESR, RF, and anti‐CCP positivity; and NSAID, glucocorticoid, or methotrexate use. The median followup time for the ever and never TNFα inhibitor users was 44.9 months (interquartile range [IQR] 23.7–73.0 months) and 37.1 months (IQR 16.3–65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNFα inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person‐years (P = 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNFα inhibitor users was 0.49 (95% confidence interval 0.24–0.99, P = 0.049) compared to the never users. Conclusion: In this inception RA cohort, anti‐TNFα use was associated with a 51% reduction in risk of developing diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.20657

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 90

Metadata

Authors
Antohe, J. L., Bili, A., Sartorius, J. A., Kirchner, H. L., Morris, S. J., Dancea, S., & Wasko, M. C. M.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2012-01-25
Volume
64
Issue
2
Pages
215-221
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2015923223
Cited by
90
References
5
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy. https://app.cochat.ai/papers/10.1002/acr.20657
The paper
Antohe, J. L., Bili, A., Sartorius, J. A., Kirchner, H. L., Morris, S. J., Dancea, S., & Wasko, M. C. M. (2012). Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy. Arthritis Care & Research. https://doi.org/10.1002/acr.20657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.